Harmony Biosciences Holdings, Inc. · NASDAQ:HRMY
Harmony Biosciences — Q2 2024 Earnings Presentation
14 slides from Harmony Biosciences's earnings presentation, Aug 6, 2024
Slide 1: Q2 2024 Financial Results
Tara Living with narcolepsy Taking WAKIX since 2020 Q2 2024 Financial Results August 6, 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward‐looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Hol
Slide 3: WAKIX Net Revenue Performance
WAKIX® Net Revenue Performance CONFIDENT IN WAKIX BEING A POTENTIAL $1B+ OPPORTUNITY IN NARCOLEPSY ALONE WAKIX Net Revenue ($M) HIGHLIGHTS ▪ Durable sales growth into year five on the market with 29% growth year-over-year ▪ Underlying demand drove continued revenue 29% growth $172.8 – Strong patient
Slide 4: Solid Business Fundamentals Driving Growth
Solid Business Fundamentals Driving Growth 7000 ~Approximate Patient Counts ~6,550 Q2 24 Highlights +250 +150 6000 +350 +350 +350 ~Average # of Patients on WAKIX 5000 +200 +300 On our way to a +300 $1B+ opportunity +400 4000 +100 in narcolepsy +300 ~6,550 Average +300 number of 3000 +400 patients on
Slide 5: Prescriber Dynamics Support Continued WAKIX Growth in Narcolepsy
Prescriber Dynamics Support Continued WAKIX® Growth in Narcolepsy: Broad Clinical Utility HCPs enrolled in Depth of prescribing ~4,000 oxybate REMS in oxybate REMS enrolled HCPs HCPs not WAKIX Breadth of prescribing ~5,000 enrolled in oxybates REMS growth in HCPs not enrolled in oxybate REMS ~9,000
Slide 6: Robust Late-Stage Pipeline
Robust Late-Stage Pipeline Product / Indication Pre-IND Phase 1 Phase 2 Phase 3 Regulatory Filing Marketed Product Milestone WAKIX® EDS in Narcolepsy (Adults) Cataplexy in Narcolepsy (Adults) EDS in Narcolepsy (Pediatric) Approved June 21, 2024 Pitolisant Idiopathic Hypersomnia (IH) Submit sNDA 4Q20
Slide 7: Strengthening Our Leadership Position in Sleep/Wake: Pitolisant LCM
Strengthening Our Leadership Position in Sleep/Wake: Pitolisant LCM Addressing Unmet Medical Needs With Meaningfully Differentiated Product Profiles Higher Dose, Pitolisant-HD EDS & Well tolerated; Gastro-Resistant Fatigue Non-scheduled No titration Enhanced PDUFA 2028 Cataplexy safety profile coati
Slide 8: Extending The Pitolisant Franchise To the Mid 2040s
Strengthening Our Leadership Position in Sleep/Wake: Extending The Pitolisant Franchise To the Mid 2040s 2019 2026 2028 2030 2040 WAKIX (LOE Sept 2030*) Pitolisant-GR (PDUFA Date 2026) Pitolisant-HD (PDUFA Date 2028) ▪ Two meaningfully differentiated product profiles building off WAKIX with PDUFAs p
Slide 9: Pitolisant High-Dose (HD) Formulation: Differentiated Product Profile
Pitolisant High-Dose (HD) Formulation: Differentiated Product Profile Attributes Development Plan Potential differentiated features Higher dose Up to 2x compared to current Better efficacy in EDS/cataplexy; highest WAKIX labeled dose Higher POS for fatigue in narcolepsy Optimized PK Pilot PK study H
Slide 10: Financial Highlights
Financial Highlights Three Months Ended Six Month Ended (In millions, USD) June 30, 2024 June 30, 2024 29% 29% $327.4 $172.8 $253.3 Net Product $134.2 Revenue Q2 2023 Q2 2024 2023 YTD 2024 YTD 32% 28% Non-GAAP $86.6 $111.3 $60.6 Adjusted $45.9 Net Income(1) Q2 2023 Q2 2024 2023 YTD 2024 YTD $429.6 $
Slide 11: Financial Summary
Financial Summary (In millions, USD) Three Months Ended Six Months Ended June 30, % Change June 30, % Change Totals may not foot due to rounding 2024 2023 2024 2023 Net Product Revenue $172.8 $134.2 29% $327.4 $253.3 29% Cost of Product Sold 32.1 25.0 28% 59.6 45.8 30% Total Operating Expenses $119.
Slide 12: GAAP vs NON-GAAP Reconciliation
GAAP vs NON-GAAP Reconciliation (In millions, USD) Three Months Ended Six Months Ended June 30, June 30, Totals may not foot due to rounding 2024 2023 2024 2023 GAAP net income $11.6 $34.3 $49.9 $63.8 Non-cash interest expense(1) 0.2 0.4 0.4 0.8 Depreciation 0.1 0.1 0.3 0.2 Amortization(2) 6.0 6.0 1
Slide 13: Reiterates 2024 Net Revenue Guidance
Reiterates 2024 Net Revenue Guidance CONFIDENT IN WAKIX BEING A POTENTIAL $1B+ OPPORTUNITY IN NARCOLEPSY ALONE WAKIX ANNUAL NET REVENUE ($M) $700-$720 Reiterates $582 2024 Guidance $438 $700-$720M $305 $160 2020 2021 2022 2023 2024 Guidance 13
Slide 14: Chris, living with narcolepsy
Chris Living with narcolepsy Taking WAKIX since 2021
Harmony Biosciences Holdings — Q2 2024 Earnings Presentation on 6ix